Prescribing Information: Great Britain | Northern Ireland


By clicking the links above, you will leave this page and be taken to the EMC PI portal website.




JOIN THE FIGHT TO ELIMINATE CERTAIN HPV-RELATED CANCERS BY VACCINATION AGAINST HPV WITH GARDASIL® 9



HOW DOES HUMAN PAPILLOMAVIRUS (HPV) PUT YOUR PATIENTS AT RISK?



HOW CAN YOU PROTECT YOUR PATIENTS AGAINST **CERTAIN HPV-RELATED CANCERS?**




*This observational study used modelling data from a total of 13.7 million years of follow up of women aged 20 to younger than 30 years old, across three different cohorts.7 Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02178-4/fulltext

WHO IS ELIGIBLE FOR HPV VACCINATION?

The World Health Organisation is aiming for the ambitious target of eliminating cervical cancer within the century. 9 This reflects the high uptake rates and efficacy of vaccines in preventing infection with cancer-inducing high-risk HPV type

- The HPV programme is primarily delivered by the School Age Immunisation Services (SAIS) for year 8/S1.8
- GP practices may offer HPV vaccination to people aged over 14 years and less than 25 years either opportunistically or when it is requested - For girls born after 1st September 1991 and boys born after 1st September 2006.8
 - » Offer HPV vaccination to people aged over 14 years and less than 25 years either opportunistically or when it is requested.



Gardasil® 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases: 10,11

- Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types
- Genital warts (Condyloma acuminata) caused by specific HPV types

Please refer to the Summary of Product Characteristics for further information prior to making any prescribing decisions. 10,11

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme Limited (Tel: 0208 154 8000). By clicking the above link, you will leave the MSD website and be taken to the MHRA website.

References: 1. Chesson HW, et al. Sex Transm Dis. 2014;4(11):660-664; 2. NHS. Human papillomavirus (HPV). May 2022. Available at: https://www.nhs.uk/conditions/human-papilloma-virus-hpv/ (accessed March 2023); 3. National Cancer Institute, HPV and Cancer. September 2022. Available at: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer (accessed March 2023); 4. Lin C, et al. Lancet Infect Dis. 2018;18:198–206; 5. The Catalan Institute of Oncology and the International Agency for Research on Cancer Information Centre on HPV and Cancer. United Kingdom Human

Papillomavirus and Related Cancers, Fact Sheet 2021. October 2021. Available at: https://hpvcentre.net/statistics/reports/GBR_FS.pdf (accessed March 2023); 6. UK Health Security Agency (UKHSA) (2019). Immunisation against infectious diseases (The Green Book) Chapter 18a Human papillomavirus (HPV). https://www.gov.uk/government/publications/human-papillomavirus-hpv-the-green-book-chapter-18a (accessed March 2023); 7. Falcaro M, et al. Lancet. 2021; 389:2084–2092; 8. NHS England and NHS Improvement. GP letter on vaccination and immunisation changes for 2021/22. March 2021. Available at: https://www. england.nhs.uk/wp-content/up-loads/2021/03/B0434_Update-on-vaccination-and-immunisation-changes-for-202122-v4.pdf (accessed March 2023); 9. World Health Organization. World Health Assembly adopts global strategy to accelerate cervical cancer elimination. August 2020. Available at: https://www.who.int/news/item/19-08-2020-world-health-assembly-adopts-global-strategy-to-accelerate-cervical-cancer-elimination (accessed March 2023);

10. Gardasil® 9 (Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed). Summary of Product Characteristics (SPC) for GB. Available at: https://www.emcpi.com/pi/32240 (accessed March 2023); 11. Gardasil® 9 (Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed). Summary of Product Characteristics (SPC) for NI. Available at: https://www.emcpi.com/pi/ni/496 (accessed March 2023).

Abbreviations: EMC, European Medicines Agency; HPV, human papillomavirus; NHS, National Health Service; PI, prescribing information; SPC, Summary of Product Characteristics. Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom.

Registered in England No. 233687

© Merck Sharp & Dohme (UK) Limited 2023. All rights reserved. GB-GSL-00401 | August 2023

